NASDAQ · Biotechnology

ENLV (ENLV) Stock

$2.12 -5.36% NASDAQ: ENLV Healthcare

Valuation

MetricValue
Price$2.12
Market Cap$35.68M
P/E Ratio0.03
P/B Ratio0.01
P/S Ratio0.00
EPS (TTM)$25.48
52-Week High$7.40
52-Week Low$0.44
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE63.88%
ROA53.12%
ROCE-0.78%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio193.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-19.0M$-26.0M$-29.0M$-16.0M$-15.0M
Net Profit$-14.0M$-31.0M$-29.0M$-15.0M$1.2B
EPS$-0.54$-2.31$-1.56$-0.73$25.48
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$95.0M$68.0M$37.0M$28.0M$2.3B
Total Liabilities$10.0M$11.0M$7.0M$4.0M$392.0M
Cash$11.0M$48.0M$1.0M$3.0M$2.0M
Borrowings$1.0M$5.0M$1.0M$1.0M$1.0M

Latest News

Enlivex Therapeutics Granted Patent in Australia for Allocetra to Treat Osteoarthritis MT Newswires · Jun 15, 2026 Enlivex advances Allocetra while expanding into prediction markets Proactive · May 11, 2026 Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress GlobeNewswire · Apr 23, 2026 H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook Insider Monkey · Apr 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-18.0M$-24.0M$-24.0M$-13.0M$-10.0M
Investing Cash Flow$-40.0M$54.0M$-26.0M$9.0M$-1.0M
Financing Cash Flow$8.0M$0$0$0$0
Net Cash Flow$5.0M$39.0M$-49.0M$3.0M$-1.0M
Free Cash Flow$-19.0M$-32.0M$-24.0M$-13.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-64.87%
Quick Ratio193.24
Interest Coverage—
Return 1Y-67.59%
Return 3Y-83.25%
Return 5Y-94.66%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About ENLV

ENLV is led by CEO Oren Hershkovitz, employs 71 people, headquartered in IL, publicly traded since 2014.

ENLV stock trades at $2.12 with a market capitalization of $35.68M. The stock is valued at a price-to-earnings (P/E) ratio of 0.03, price-to-book of 0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.44 and $7.40, and currently trades 71.4% below its 52-week high.

On profitability, ENLV generates a return on equity (ROE) of 63.88% — well above the market average, a sign of a high-quality business, return on capital employed of -0.78%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides